TIDMAGL
RNS Number : 6588V
Angle PLC
16 April 2021
For immediate release 16 April 2021
ANGLE plc ("the Company")
FIRST LARGE-SCALE PHARMA SERVICES CONTRACT SECURED
Contract worth up to US$1.2 million with potential for further
contracts from the same customer
Parsortix system being utilised in cancer drug trials for liquid
biopsy longitudinal monitoring which is not possible with tissue
biopsies
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is delighted to announce that the Company has secured its
first large-scale pharma services contract. The customer, a pharma
company with numerous cancer drugs under development and revenues
exceeding US$1 billion per annum, has selected ANGLE's Parsortix(R)
system to undertake longitudinal monitoring (i.e. before, during
and after drug intervention) of patients in three separate global
clinical trials in prostate cancer and other locally advanced and
metastatic solid tumours.
The contract is expected to be worth up to US$1.2 million over
some 18 months. The work relates to a large Phase III prostate
cancer study and two smaller Phase I studies. The Phase I studies,
if successful, could progress to larger Phase II studies and, if
successful, much larger Phase III studies.
The services cover the capture, harvest and analysis of
circulating tumor cells (CTCs) and CTC clusters. Samples are being
shipped from multiple study centres to ANGLE's clinical
laboratories in the UK and United States for analysis using the
Parsortix system.
The contract represents the first large-scale adoption of the
Parsortix system for processing patient blood samples to help
inform decision making in cancer drug trials. Importantly, the
customer recognises the advantage in capturing mesenchymal as well
as epithelial cancer cells and the importance that CTC clusters as
well as single CTCs may have in the progression of disease,
metastasis, and drug resistance.
The Parsortix liquid biopsy has particular advantages in
capturing intact cancer cells including mesenchymal cells and
clusters and provides the opportunity for longitudinal testing in a
clinical setting, which is not possible with tissue biopsy. ANGLE
believes that longitudinal monitoring of CTCs will prove highly
attractive to the pharma industry looking for new insights in
cancer drug trials.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"We are delighted to have contracted with a pharma company
developing numerous cancer drugs and look forward to working
closely with them on their trials. ANGLE believes that there is a
substantial business opportunity in providing services to pharma
and biotech customers to support cancer drug trials. This contract
demonstrates that our investment in clinical laboratories and a
pharma services business, a key use of proceeds from our
fundraising in October 2020, is already delivering. We look forward
to announcing further progress on the expansion of this important
business area for ANGLE in due course."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Teddy Whiley
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2015.
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen as being an intact cell they allow
DNA, RNA and protein analysis and may provide comparable analysis
to a tissue biopsy. Because CTC analysis is a non-invasive process,
unlike tissue biopsy, it can be repeated as often as needed. This
is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the
status of a patient's tumor. In addition, the live CTCs harvested
by the Parsortix system can be cultured, which offers the potential
for testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
The Parsortix system has a CE Mark in Europe for the indicated
use and, in the United States, a De Novo Submission has been made
to FDA for the Parsortix(R) PC1 system seeking FDA clearance with
Class II Classification for use with metastatic breast cancer
patients. FDA clearance is seen as the global standard. ANGLE is
seeking to be the first ever FDA cleared system for harvesting CTCs
for subsequent analysis.
ANGLE has also completed two separate 200 subject clinical
studies under a program designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has
undergone further refinement and optimisation and is currently in
the process of a 200 patient clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEADTM Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is extremely sensitive
and is ideal for measuring gene expression and other markers
directly from Parsortix harvests and was used in the ovarian cancer
pelvic mass triage test to achieve best in class accuracy (AUC-ROC)
of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
41 peer-reviewed publications and numerous publicly available
posters, available on our website.
ANGLE has established clinical services laboratories in the UK
and USA to accelerate commercialisation of the Parsortix system and
act as demonstrators to support product development. The
laboratories offer services to pharmaceutical and biotech customers
for use of the Parsortix system in cancer drug trials and, once the
laboratories are accredited, and tests validated, will provide
Laboratory Developed Tests (LDTs) for patient management.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTEAPLSFEPFEFA
(END) Dow Jones Newswires
April 16, 2021 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024